314 related articles for article (PubMed ID: 35599019)
1. Application of precision medicine in clinical routine in haematology-Challenges and opportunities.
Wästerlid T; Cavelier L; Haferlach C; Konopleva M; Fröhling S; Östling P; Bullinger L; Fioretos T; Smedby KE
J Intern Med; 2022 Aug; 292(2):243-261. PubMed ID: 35599019
[TBL] [Abstract][Full Text] [Related]
2. Novel precision medicine approaches and treatment strategies in hematological malignancies.
Rosenquist R; Bernard E; Erkers T; Scott DW; Itzykson R; Rousselot P; Soulier J; Hutchings M; Östling P; Cavelier L; Fioretos T; Smedby KE
J Intern Med; 2023 Oct; 294(4):413-436. PubMed ID: 37424223
[TBL] [Abstract][Full Text] [Related]
3. Real-time quantitation of bcr-abl transcripts in haematological malignancies.
Saffroy R; Lemoine A; Brézillon P; Frénoy N; Delmas B; Goldschmidt E; Souleau B; Nedellec G; Debuire B
Eur J Haematol; 2000 Oct; 65(4):258-66. PubMed ID: 11073166
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of chronic myeloid leukemia: present and future.
Yeung CC; Egan D; Radich JP
Expert Rev Mol Diagn; 2016 Oct; 16(10):1083-1091. PubMed ID: 27552202
[TBL] [Abstract][Full Text] [Related]
6. Current trends in molecular diagnostics of chronic myeloid leukemia.
Vinhas R; Cordeiro M; Pedrosa P; Fernandes AR; Baptista PV
Leuk Lymphoma; 2017 Aug; 58(8):1791-1804. PubMed ID: 27919203
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of molecular haematology: an overview.
Bain BJ
J Assoc Physicians India; 2007 Jul; 55():503-6. PubMed ID: 17907501
[TBL] [Abstract][Full Text] [Related]
8. Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing.
Zhao H; Chen Y; Shen C; Li L; Li Q; Tan K; Huang H; Hu G
J Gene Med; 2021 Jan; 23(1):e3276. PubMed ID: 32949441
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
[TBL] [Abstract][Full Text] [Related]
10. Chronic Myeloid Leukemia: Beyond BCR-ABL1.
Zhou T; Medeiros LJ; Hu S
Curr Hematol Malig Rep; 2018 Dec; 13(6):435-445. PubMed ID: 30370478
[TBL] [Abstract][Full Text] [Related]
11. Molecular methods in diagnosis and monitoring of haematological malignancies.
Yeung DT; Parker WT; Branford S
Pathology; 2011 Oct; 43(6):566-79. PubMed ID: 21881536
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
13. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
14. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
15. Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
Romzova M; Smitalova D; Hynst J; Tom N; Loja T; Herudkova Z; Jurcek T; Stejskal L; Zackova D; Mayer J; Racil Z; Culen M
Br J Haematol; 2021 Aug; 194(3):604-612. PubMed ID: 34212373
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine in myeloid malignancies.
Westermann J; Bullinger L
Semin Cancer Biol; 2022 Sep; 84():153-169. PubMed ID: 33895273
[TBL] [Abstract][Full Text] [Related]
18. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
Moravcová J; Brdicka R
Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
[TBL] [Abstract][Full Text] [Related]
19. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
20. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
